Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease - PubMed (original) (raw)

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease

N Andreasen et al. Arch Neurol. 1999 Jun.

Abstract

Objectives: To study the diagnostic potential of the 42 amino acid form of beta-amyloid (beta-amyloid(1-42)) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), the intra-individual biological variation of CSF-beta-amyloid(1-42) level in patients with AD, and the possible effects of differential binding between beta-amyloid and apolipoprotein E isoforms on CSF-beta-amyloid(1-42) levels.

Design: A 20-month prospective follow-up study.

Setting: Community population-based sample of consecutive patients with AD referred to the Piteå River Valley Hospital, Piteå, Sweden.

Patients: Fifty-three patients with AD (mean +/- SD age, 71.4 +/- 7.4 years) diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria and 21 healthy, age-matched (mean +/- SD age, 68.8 +/- 8.0 years) control subjects.

Main outcome measures: Cerebrospinal fluid beta-amyloid(1-42) level--analyzed using enzyme-linked immunosorbent assay--and severity of dementia--analyzed using the Mini-Mental State Examination.

Results: Mean +/- SD levels of CSF-beta-amyloid(1-42) were decreased (P<.001) in patients with AD (709 +/- 304 pg/mL) compared with controls (1678 +/- 436 pg/mL). Most patients with AD (49 [92%] of 53 patients) had reduced levels (<1130 pg/mL). A highly significant correlation (r = 0.90; P<.001) between baseline and 1-year follow-up CSF-beta-amyloid(1-42) levels was found. There were no significant correlations between CSF-beta-amyloid(1-42) level and duration (r = -0.16) or severity (r = -0.02) of dementia. Low levels were also found in patients with mild dementia (Mini-Mental State Examination score, >25).

Conclusions: The sensitivity of CSF-beta-amyloid(1-42) level as a diagnostic marker for AD is high. The intra-individual biological variation in CSF-beta-amyloid(1-42) level is low. Low CSF-beta-amyloid(1-42) levels are also found in the earlier stages of dementia in patients with AD. These findings suggest that CSF-beta-amyloid(1-42) analyses may be of value in the clinical diagnosis of AD, especially in the early course of the disease, when drug therapy may have the greatest potential of being effective but clinical diagnosis is particularly difficult.

PubMed Disclaimer

Comment in

Cerebrospinal fluid opens a window on Alzheimer disease.
Galasko D. Galasko D. Arch Neurol. 1999 Jun;56(6):655-6. doi: 10.1001/archneur.56.6.655. Arch Neurol. 1999. PMID: 10369301 No abstract available.

Cited by

Leveraging a large language model to predict protein phase transition: A physical, multiscale, and interpretable approach.
Frank M, Ni P, Jensen M, Gerstein MB. Frank M, et al. Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2320510121. doi: 10.1073/pnas.2320510121. Epub 2024 Aug 7. Proc Natl Acad Sci U S A. 2024. PMID: 39110734
Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia.
Colmant L, Boyer E, Gerard T, Sleegers K, Lhommel R, Ivanoiu A, Lefèvre P, Kienlen-Campard P, Hanseeuw B. Colmant L, et al. Int J Mol Sci. 2024 Jan 18;25(2):1173. doi: 10.3390/ijms25021173. Int J Mol Sci. 2024. PMID: 38256246 Free PMC article.
Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease.
Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, Blennow K, Hansson O, Zetterberg H. Daborg J, et al. J Neural Transm (Vienna). 2012 Jul;119(7):789-97. doi: 10.1007/s00702-012-0797-8. Epub 2012 Apr 10. J Neural Transm (Vienna). 2012. PMID: 22488444
β-Amyloids and Immune Responses Associated with Alzheimer's Disease.
Kolobova E, Petrushanko I, Mitkevich V, Makarov AA, Grigorova IL. Kolobova E, et al. Cells. 2024 Sep 28;13(19):1624. doi: 10.3390/cells13191624. Cells. 2024. PMID: 39404388 Free PMC article. Review.
Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders.
Eckerström C, Svensson J, Kettunen P, Jonsson M, Eckerström M. Eckerström C, et al. Alzheimers Dement (Amst). 2021 Apr 1;13(1):e12031. doi: 10.1002/dad2.12031. eCollection 2021. Alzheimers Dement (Amst). 2021. PMID: 33816750 Free PMC article.

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease - PubMed (original) (raw)